Cisplatin pharmacokinetics in a patient with renal dysfunction

Archie W. Prestayko, Fredrich C. Luft, Lawrence Einhorn, Stanley T. Crooke

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Plasma and urine platinum concentrations were measured by atomic absorption spectrophotometry during a three‐day course of cisdiamminedichloroplatinum (DDP, cis‐platinum, cisplatin) therapy in a patient with acute renal failure who was being treated with hemodialysis. Twenty‐four hour urine collections, obtained during the oliguric phase, accounted for only 0.36–0.56 percent of the daily DDP dose. The plasma t1/2β of platinum was approximately 240 hours after the last DDP dose. Platinum could be measured in the dialysate only during the first two hours after DDP administration. Although the data show that the t1/2β of DDP is prolonged three fold in a patient with profound renal failure, the clinical implications of these findings await further studies.

Original languageEnglish (US)
Pages (from-to)183-188
Number of pages6
JournalMedical and Pediatric Oncology
Issue number1
StatePublished - 1978


  • cisplatin
  • pharmacokinetics
  • renal dysfunction

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cisplatin pharmacokinetics in a patient with renal dysfunction'. Together they form a unique fingerprint.

Cite this